





Edgar Filing: Edge Therapeutics, Inc. - Form 8-K

Item 5.07 – Submission of Matters to a Vote of Security Holders

The 2016 Annual Meeting of Stockholders (the “Annual Meeting”) of Edge Therapeutics, Inc. (“Edge”) was held on June 21, 2016. A quorum was present at the Annual Meeting. Matters submitted to the stockholders and voted upon at the meeting, which are more fully described in Edge’s Proxy Statement filed with the Securities and Exchange Commission on April 28, 2016, were (1) the election of Kurt Conti, Liam Ratcliffe, M.D., Ph.D., and Robert Spiegel, M.D. as Class A directors to Edge’s board of directors to hold office until the 2019 Annual Meeting of Stockholders and (2) the ratification of the selection of KPMG LLP as Edge’s independent registered public accounting firm for the fiscal year ending December 31, 2016. At the Annual Meeting, Edge’s stockholders approved the two proposals, and the final results were as follows:

(1) Election of Kurt Conti, Liam Ratcliffe, M.D., Ph.D. and Robert Spiegel, M.D. as a Class A directors, to hold officer until the 2019 Annual Meeting of Stockholders:

| Nominees                    | For        | Withheld  | Broker Non-Votes |
|-----------------------------|------------|-----------|------------------|
| Kurt Conti                  | 14,883,742 | 1,214,896 | 6,177,093        |
| Liam Ratcliffe, M.D., Ph.D. | 15,871,954 | 226,684   | 6,177,093        |
| Robert Spiegel, M.D.        | 14,818,598 | 1,280,040 | 6,177,093        |

(2) Ratification of the selection of KPMG LLP as Edge’s independent registered public accounting firm for the year ending December 31, 2016:

| For        | Against | Abstain | Broker Non-Votes |
|------------|---------|---------|------------------|
| 22,227,202 | 47,819  | 710     | 0                |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 24, 2016 Edge Therapeutics, Inc.

By: /s/ Andrew J. Einhorn  
Name: Andrew J. Einhorn  
Title: Chief Financial Officer

---